Supplementary Figure S7 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer

Key Points

NCOA4 modulates prostate cancer sensitivity to ferroptosis-inducing drugs, enhancing therapeutic options.
Key evidence reveals that altering NCOA4 activity impacts drug efficacy, promoting ferroptosis in cancer cells.
Observational analysis in multicohort studies highlights the association between enhancer variants and therapy response.
Findings suggest the potential for targeted precision therapy based on individual enhancer variations in patients.

We only have this paper's title and publication details.

Analysis shows NCOA4 modulates drug sensitivity in prostate cancer, suggesting new treatment avenues.

NCOA4 modulates prostate cancer sensitivity to ferroptosis-inducing drug.

No takes yet. Share an insight, caveat, or question.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share